Evidence map›Paper›PMID 37407829›Full record

ArticleNature2023

Author Correction: A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.

Corey Momont, Ha V Dang, Fabrizia Zatta, Kevin Hauser, Caihong Wang, Julia di Iulio, Andrea Minola, Nadine Czudnochowski, Anna De Marco, Kaitlin Branch and 25 more

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 5 institutions in 3 countries.

Corey Momont *Vir Biotechnology, San Francisco, CA, USA.
Ha V Dang *Vir Biotechnology, San Francisco, CA, USA.
Fabrizia Zatta *Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Kevin Hauser *Vir Biotechnology, San Francisco, CA, USA.
Caihong WangVir Biotechnology, St. Louis, MO, USA.
Julia di IulioVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9343-127X
Andrea MinolaHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Nadine CzudnochowskiVir Biotechnology, San Francisco, CA, USA.
Anna De MarcoHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Kaitlin BranchVir Biotechnology, San Francisco, CA, USA.
David DonermeyerVir Biotechnology, St. Louis, MO, USA.
Siddhant VyasVir Biotechnology, San Francisco, CA, USA.
Alex ChenVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2620-5066
Elena FerriVir Biotechnology, San Francisco, CA, USA.
Barbara GuarinoHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Abigail E PowellVir Biotechnology, San Francisco, CA, USA.
Roberto SpreaficoVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8282-7658
Samantha S YimVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0009-0007-8567-3501
Dale R BalceVir Biotechnology, San Francisco, CA, USA.
Istvan BarthaVir Biotechnology, San Francisco, CA, USA.
Marcel MeuryVir Biotechnology, San Francisco, CA, USA.
Tristan I CrollCambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK.
David M BelnapSchool of Biological Sciences, Department of Biochemistry, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0002-0619-7487
Michael A SchmidHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-1137-9322
William Timothy SchaiffVir Biotechnology, St. Louis, MO, USA.
Jessica L MillerVir Biotechnology, San Francisco, CA, USA.
Elisabetta CameroniHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Amalio TelentiVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6290-7677
Herbert W VirginVir Biotechnology, San Francisco, CA, USA.
Laura E RosenVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8030-0219
Lisa A PurcellVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-9565-2030
Antonio LanzavecchiaHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Gyorgy SnellVir Biotechnology, San Francisco, CA, USA. gsnell@vir.bio.ORCID http://orcid.org/0000-0003-1475-659X
Davide CortiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.ORCID http://orcid.org/0000-0002-5797-1364
Matteo Samuele PizzutoHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. mpizzuto@vir.bio.ORCID http://orcid.org/0000-0001-5776-654X
VIR Biotechnology (United States) · USVir Biotechnology (Switzerland) · CHUniversity of Cambridge · GBUniversity of Utah · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37407829
PMCPMC10356599
OpenAlexW4383265756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.